Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

DSpace Repository

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Author: Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F. Stephen; Schachter, Jacob; Pavlick, Anna C.; Lewis, Karl D.; Cranmer, Lee D.; Blank, Christian U.; O'Day, Steven J.; Ascierto, Paolo A.; Salama, April K. S.; Margolin, Kim A.; Loquai, Carmen; Eigentler, Thomas K.; Gangadhar, Tara C.; Carlino, Matteo S.; Agarwala, Sanjiv S.; Moschos, Stergios J.; Sosman, Jeffrey A.; Goldinger, Simone M.; Shapira-Frommer, Ronnie; Gonzalez, Rene; Kirkwood, John M.; Wolchok, Jedd D.; Eggermont, Alexander; Li, Xiaoyun Nicole; Zhou, Wei; Zernhelt, Adriane M.; Lis, Joy; Ebbinghaus, Scot; Kang, S. Peter; Daud, Adil
Tübinger Autor(en):
Eigentler, Thomas Kurt
Published in: Lancet Oncology (2015), Bd. 16, H. 8, S. 908-918
Verlagsangabe: Elsevier Science Inc
Language: English
Full text: http://dx.doi.org/10.1016/S1470-2045(15)00083-2
ISSN: 1470-2045
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)